Back

Structural epitope profiling identifies antibodies associated with critical COVID-19 and long COVID

Kearns, P. K. A.; Badonyi, M.; Lee, K.; Fleming, O.; Gerasimivicous, L.; Benton, S.; Guy, J.; Neilson, S.; Wise, H.; Jenks, S.; Templeton, K.; Dold, C.; Lambe, T.; Mentzer, A. J.; Knight, J.; Pollard, A.; COMBAT, ; Menon, M.; Hussell, T.; CIRCO, ; McWhirter, L.; Carson, A.; Fragkoudis, R.; Rosser, S.; Cavanagh, D.; Marsh, J. A.; Kleinjan, D. A.; Gilbert, N.

2022-07-12 infectious diseases
10.1101/2022.07.11.22277368
Show abstract

Even within a single protein, antibody binding can have beneficial, neutral, or harmful effects during the response to infection. Resolving a polyclonal antibody repertoire across a pathogens proteome to specific epitopes may therefore explain much of the heterogeneity in susceptibility to infectious disease. However, the three-dimensional nature of antibody-epitope interactions makes the discovery of non-obvious targets challenging. We implemented a novel computational method and synthetic biology pipeline for identifying epitopes that are functionally important in the SARS-CoV-2 proteome and identified an IgM-dominant response to an exposed Membrane protein epitope which to our knowledge is the strongest correlate of severe disease identified to date (adjusted OR 72.14, 95% CI: 9.71 - 1300.15), stronger even than the exponential association of severe disease with age. We also identify persistence (> 2 years) of this IgM response in individuals with longCOVID, and a correlation with fatigue and depression symptom burden. The repetitive arrangement of this epitope and the pattern of isotype class switching is consistent with this being a previously unrecognized T independent antigen. These findings point to a coronavirus host-pathogen interaction characteristic of severe virus driven immune pathology. This epitope is a promising vaccine and therapeutic target as it is highly conserved through SARS-CoV-2 variant evolution in humans to date and in related coronaviruses (e.g. SARS-CoV), showing far less evolutionary plasticity than targets on the Spike protein. This provides a promising biomarker for longCOVID and a target to complement Spike-directed vaccination which could broaden humoral protection from severe or persistent disease or novel coronavirus spillovers. One-Sentence SummaryUsing a novel protein-structure-based B cell epitope discovery method with a wide range of possible applications, we have identified a simple to measure host-pathogen antibody signature associated with severe COVID-19 and longCOVID and suggest the viral Membrane protein contains an epitope that acts as a T independent antigen during infection triggering extrafollicular B cell activation.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Nature Communications
based on 483 papers
Top 3%
15.2%
2
Nature
based on 58 papers
Top 0.1%
10.1%
3
Immunity
based on 11 papers
Top 0.1%
7.5%
4
Cell Reports Medicine
based on 49 papers
Top 0.3%
6.3%
5
Cell Reports
based on 25 papers
Top 0.1%
5.3%
6
Cell
based on 28 papers
Top 0.2%
5.3%
7
Science
based on 46 papers
Top 0.9%
5.3%
50% of probability mass above
8
Science Translational Medicine
based on 40 papers
Top 0.7%
4.4%
9
JCI Insight
based on 63 papers
Top 2%
4.4%
10
Nature Medicine
based on 88 papers
Top 3%
2.9%
11
Nature Genetics
based on 72 papers
Top 5%
2.4%
12
iScience
based on 74 papers
Top 2%
2.4%
13
Nature Immunology
based on 14 papers
Top 0.6%
2.3%
14
The Journal of Immunology
based on 19 papers
Top 0.9%
1.8%
15
Scientific Reports
based on 701 papers
Top 69%
1.7%
16
Science Immunology
based on 15 papers
Top 0.7%
1.6%
17
Frontiers in Immunology
based on 140 papers
Top 5%
1.6%
18
mBio
based on 34 papers
Top 2%
1.3%
19
Clinical & Translational Immunology
based on 14 papers
Top 0.4%
1.3%
20
Proceedings of the National Academy of Sciences
based on 100 papers
Top 11%
1.2%
21
PLOS Pathogens
based on 35 papers
Top 2%
1.2%
22
Science Advances
based on 52 papers
Top 5%
0.8%
23
Journal of Clinical Investigation
based on 50 papers
Top 4%
0.8%
24
EMBO Molecular Medicine
based on 15 papers
Top 3%
0.7%
25
eLife
based on 262 papers
Top 35%
0.7%
26
eBioMedicine
based on 82 papers
Top 9%
0.7%